September 13, 2017

Adamas to Host Investor and Analyst Meeting on September 18, 2017

EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from 8:00 a.m. - 11:00 a.m. ET in New York, NY. The event will be hosted by members of the Adamas executive management team and will feature presentations from Key Opinion Leaders in the fields of Parkinson's disease and Multiple sclerosis.

The event will provide an overview of the market opportunity and commercial plans for GOCOVRI™ (amantadine) extended release capsules, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. In addition, the company will provide an overview of its clinical development programs: ADS-5102, a product candidate for the treatment of multiple sclerosis walking impairment and ADS-4101, a product candidate for the treatment of partial onset seizures in patients with epilepsy.

Attendance at this event is by invitation only. For additional event details, please contact Marcy Nanus at mnanus@troutgroup.com. A live webcast of the event can be accessed on the Investors section of the Adamas website at http://ir.adamaspharma.com/events.cfm and will be available for replay until October 18, 2017.

About GOCOVRI
GOCOVRI is the first and only medicine approved by the FDA for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. For more information about GOCOVRI, including Important Safety Information, please see the full Prescribing Information available at www.GOCOVRI.com.

About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment and additional indications in Parkinson's disease, and ADS-4101, a high-dose, modified-release lacosamide in Phase 1 clinical development for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas licensed assets are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.

NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.

Forward-looking Statements
Statements contained in this press release regarding expected future events are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding the expected benefits of GOCOVRI, physician and patient access in fourth quarter 2017 and launch of GOCOVRI (amantadine) extended release capsules (previously ADS-5102) in January 2018 for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and Adamas' plans to offer a number of programs providing patient access support throughout the course of treatment, along with commercial copay assistance and financial assistance for patients who are uninsured or underinsured. Words such as "potentially," "expected," "will," "plans" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas' research, clinical, development, and commercial activities relating to ADS-5102 and ADS-4101, and the regulatory and competitive environment and Adamas' business in general, see Adamas' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2017. Investors are cautioned not to place undue reliance on these forward-looking

statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release.

Contact:

Ashleigh Barreto

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

ir@adamaspharma.com

Primary Logo

Source: Adamas Pharmaceuticals, Inc.